Clinical trial · Observational
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
NCT02834884CI-TRIAL-00115803SPECTArecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| All Tumor Types | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 2148 MRD | Genetic | — | UNRESOLVED |
| RP-1759 AYA/TYA | Genetic | — | UNRESOLVED |
| RP-1828 IMMUcan | Genetic | — | UNRESOLVED |
| RP-1843 Arcagen | Genetic | — | UNRESOLVED |
| RP-1920 BioRadon | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- RP-1828 IMMUcan (CLOSED for recruitment since August 2024)
- description
- The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions. Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary
- interventionNames
- Genetic: RP-1828 IMMUcan
- label
- RP-1759 AYA/TYA (CLOSED for recruitment since December 2021)
- description
- The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials. Tumor type: CNS
- interventionNames
- Genetic: RP-1759 AYA/TYA
- label
- RP-1843 Arcagen (CLOSED for recruitment since November 2022)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
* Patients with pathologically confirmed selected tumor types (at site or centrally); * Mandatory availability of adequate human biological material (HBM); * Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; * Age ≥ 12 years; * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; * Written informed consent according to applicable legal and ethical requirements;
References
Publications (0)
Data not yet available
No reference posted for this study.